Preferred Label : Loncastuximab Tesirine;
NCIt synonyms : Anti-CD19 PBD-conjugate ADCT-402; ADC ADCT-402; Loncastuximab Tesirine-lpyl;
NCIt definition : An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody
conjugated, via a cleavable linker comprised of valine-alanine and maleimide, to a
cytotoxic, cross-linking agent pyrrolobenzodiazepine (PBD) dimer, which targets DNA
minor grooves, with potential antineoplastic activity. Upon administration, the monoclonal
antibody portion of loncastuximab tesirine targets the cell surface antigen CD19 on
various cancer cells. Upon antibody/antigen binding and internalization, the cytotoxic
PBD moiety is released. The imine groups of the PBD moiety bind to the N2 positions
of guanines on opposite strands of DNA. This induces interstrand cross-links in the
minor groove of DNA and inhibits DNA replication, which inhibits the proliferation
of CD19-overexpressing tumor cells. CD19, a transmembrane receptor and tumor-associated
antigen (TAA), is expressed on a number of B-cell-derived cancers.;
UNII : 7K5O7P6QIU;
CAS number : 1879918-31-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1879918-31-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Zynlonta;
Molecule name : ADCT-402; MT-2111; MT 2111;
NCI Metathesaurus CUI : CL504277;
Codes from synonyms : 53908;
Origin ID : C125549;
UMLS CUI : C5203804;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
